Literature DB >> 31912110

A rare case of a double high-risk gastrointestinal stromal tumor of jejunum with KIT-negative∕PDGFRA-positive immunophenotype.

Mădălina Boşoteanu1, Gabriela Izabela Bălţătescu, Mariana Deacu, Mariana Aşchie, Cătălin Adrian Boşoteanu.   

Abstract

Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors that represent the second most common type in the gastrointestinal system, but clinical outcomes vary due to complex molecular changes. The aim of our study is to highlight a unique case of a 5th decade male, presenting a double primary GIST of the jejunum, associated with a rare immunophenotype and with a high risk of malignancy. Ancillary studies were performed using several biomarkers [cluster of differentiation (CD) 117∕c-kit, discovered on GIST1 (DOG1), desmin, S-100, vimentin, cytokeratin 7 (CK7), Ki67, actin, platelet-derived growth factor receptor alpha (PDGFRA) and CD34], in order to confirm the diagnosis and to evaluate prognostic and predictive factors. A KIT-negative∕PDGFRA-positive immunophenotype was obtained in our case and it was associated with a poor prognosis. Its unfavorable clinical evolution was sustained by recurrence as malignant (GIST) with dedifferentiation and metastases developed in less than one year after the initial diagnosis. Clinico-morphological features of GISTs with an impact on survival must be identified and a tailored therapy should be applied for each case.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31912110

Source DB:  PubMed          Journal:  Rom J Morphol Embryol        ISSN: 1220-0522            Impact factor:   1.033


  2 in total

1.  Morphological and Ancillary Features of Uterine Leiomyosarcoma: Case Report.

Authors:  Mădălina Boșoteanu; Raluca Ioana Vodă; Mariana Așchie; Luana-Andreea Bosoteanu; Gabriela Izabela Bălțătescu
Journal:  Clin Pathol       Date:  2022-06-27

2.  Enhancer of zeste homolog 2-mediated paired box 8 methylation promotes gastrointestinal stromal tumor progression through Wnt4 downregulation.

Authors:  Zhiguo Miao; Fanggeng Wu; Haiyun Wei; Zhipeng Luo; Kun Wu; Jiangnan Zhang
Journal:  Cancer Gene Ther       Date:  2021-01-21       Impact factor: 5.854

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.